Home

CFAR

Personnel

Questions

Mission

Glossary

Clinical Trials

Consents

Feedback

CAB

Links

CLINICAL TRIAL CONSENTS:

ACTG Studies

 

Pre-Screen IC V3 2/12/19 *EFFECTIVE 2/26/19

Cryopreservation IC V10 4/5/19 *EFFECTIVE 4/25/19

A5128 V4 IC V10 7/9/18 *EFFECTIVE 9/11/18

A5320 V2 IC V9 7/11/18 *EFFECTIVE 7/18/18

A5321 V3 IC V9 08/15/18 *EFFECTIVE 5/6/19

A5322 V2 IC V7 5/2/18 *EFFECTIVE 4/3/19

A5324 V2 IC V9 9/13/18 *EFFECTIVE 11/15/18

A5329 V2 IC V6 7/21/17 *EFFECTIVE 8/23/17

A5332 V5 IC V12 4/25/19 *EFFECTIVE 5/1/19

A5333s V4 IC V7 4/18/18 *EFFECTIVE 12/12/18

A5335s V1 IC V4 7/21/17 *EFFECTIVE 8/3/17

A5336 V2 IC V3 10/5/16 *EFFECTIVE 3/27/17

A5341s V2 IC V5 3/14/19 *EFFECTIVE 3/18/19

A5354 V1 IC V4 5/8/19 *EFFECTIVE 5/29/19

A5354 Optional Evals V1 IC V3 11/22/17 *EFFECTIVE 3/25/19

A5359 V1 IC V4 8/29/19 *EFFECTIVE 9/20/19

A5360 V1 IC V5 3/4/19 *EFFECTIVE 3/28/19

A5361s V1 IC V3 4/9/18 *EFFECTIVE 3/21/19

A5366 V1 IC V3 3/26/18 *EFFECTIVE 4/10/18

A5369 V1 IC V5 5/3/19 *EFFECTIVE 6/12/19

A5377 V2 IC V2 4/9/19 *EFFECTIVE 5/6/19

A5378 V4 V4 VRC607 *EFFECTIVE 8/9/2018

Cocaine Use PET Scan IC V3 2/25/14 *EFFECTIVE 11/21/16

Industry Studies

AI438047 IC V4 1/27/17 *EFFECTIVE 1/27/17

AI438047 PG IC V2 1/27/17 *EFFECTIVE 1/27/17

ARBO-004 IC V2 11/1/18 *EFFECTIVE 11/8/18

C34 Gene Therapy V9 IC V8 1/8/19 *EFFECTIVE 2/12/19

C34 Gene Therapy LTFU IC V3 1/25/18 *EFFECTIVE 3/21/19

CD4CAR-ZFN V6.07-16-2019 *EFFECTIVE 9/19/19

Delaney Leukapheresis IC V3 2/12/19 *EFFECTIVE 2/14/19

Ebola Plasma IC V3 5/24/17 *EFFECTIVE 5/3/18

EV Biomarkers - Dr. Mohler IC V2 3/16/16 *EFFECTIVE 4/9/18

Gilead US380-1489 Open Label IC 5/24/19 *EFFECTIVE 6/5/19

Gilead US380-1490 Open Label IC 5/24/19 *EFFECTIVE 6/5/19

Gilead US380-4580 IC 9/18/18 *PENDING

HOPE V2 IC V3 3/13/19 *EFFECTIVE 6/11/19

Leukapheresis - Reservoirs IC V2 12/1/15 *EFFECTIVE 10/10/18

Merck MK-1439A-021 IC 7/28/17 *EFFECTIVE 8/3/17

Merck MK-1439A-021 ext IC 1/11/19 *EFFECTIVE 1/17/19

Merck MK-1439A-021 SP IC 7/28/17 *EFFECTIVE 2/13/18

Merck MK-1439A-021 ext SP IC 1/11/19 *EFFECTIVE 2/5/19

Merck MK-1439A-021 FBR IC 6/16/15 *EFFECTIVE 6/22/15

Merck MK-1439A-021Clincard IC 2/5/15 *EFFECTIVE

Merck MK-1439A-021Clincard ext IC 1/03/19 *EFFECTIVE 1/17/19

Merck MK-1439A-021Clincard ext SP IC 1/3/19 *EFFECTIVE 1/17/19

Merck MK-1439A-024 IC 7/5/17 *EFFECTIVE 7/10/17

Merck MK-1439A-024 ext IC 11/14/18 *EFFECTIVE 11/16/18

Merck MK-1439A-024 2nd ext IC 11/14/18 *EFFECTIVE 11/16/18

Merck MK-1439A-024 Clincard IC 1/27/15 *EFFECTIVE 9/26/16

Merck MK-1439A-024 Clincard ext IC 1/27/15 *EFFECTIVE 11/7/16

Merck MK-1439A-024 Clincard 2nd ext IC 2/1/18 *EFFECTIVE 2/13/18

Merck MK-1439A-024 FBR IC 6/16/15 *EFFECTIVE 6/22/15

Sangamo (znf) LTFU V4 1/8/14 *EFFECTIVE 1/30/18

Sangamo II (m-rna) LTFU V4 6/4/18 *EFFECTIVE 4/4/19

Sangamo SB-728mR Cohort 1 V12 2/24/17 *EFFECTIVE 7/20/17

Sangamo SB-728mR Cohort 2/3 V3 2/24/17 *EFFECTIVE 7/20/17

Virxsys/Adapt LTFU 3/30/12 - *EFFECTIVE 7/7/16

VRC 500 IC V1 10/21/16 - *EFFECTIVE 12/5/16

VRC 607 IC V3 6/5/17 - *EFFECTIVE 6/23/17

Zika dMAB IC V3 2/7/19 - *EFFECTIVE 2/14/19

Zika Plasma IC V3 7/24/17 - *EFFECTIVE 9/19/18